28118752|t|The impact of adjunctive guanfacine extended release on stimulant adherence in children / adolescents with attention-deficit / hyperactivity disorder
28118752|a|To assess stimulant adherence among children / adolescents with attention-deficit / hyperactivity disorder (ADHD) augmenting stimulants with guanfacine extended-release (GXR). Inclusion criteria: 6-17 years, ≥1 ADHD diagnosis, ≥1 long-acting and/or short-acting stimulant with GXR augmentation. Modified medication possession ratio (mMPR; days medication available / days in period, excluding medication holidays) was assessed; mMPR < 0.80 nonadherent. Regression models assessed change in mMPR adjusting for demographic and clinical characteristics. Among patients nonadherent to stimulants pre - augmentation (n = 165), unadjusted mean (SD) pre - and post - stimulant mMPRs were 0.68 (0.11) and 0.87 (0.16). Adjusted mean change in mMPR was 0.20 for long-acting versus 0.18 for short-acting stimulants (p = 0.34). Among patients nonadherent to stimulants, GXR augmentation was associated with increased stimulant adherence.
28118752	4	10	impact	T080	C4049986
28118752	14	24	adjunctive	T061	C0677850
28118752	25	35	guanfacine	T109,T121	C0079466
28118752	36	52	extended release	T122	C1707968
28118752	56	65	stimulant	T121	C0304402
28118752	66	75	adherence	T169	C1510802
28118752	79	87	children	T100	C0008059
28118752	90	101	adolescents	T100	C0205653
28118752	107	124	attention-deficit	T048	C0041671
28118752	127	149	hyperactivity disorder	T048	C1263846
28118752	160	169	stimulant	T121	C0304402
28118752	170	179	adherence	T169	C1510802
28118752	186	194	children	T100	C0008059
28118752	197	208	adolescents	T100	C0205653
28118752	214	231	attention-deficit	T048	C0041671
28118752	234	256	hyperactivity disorder	T048	C1263846
28118752	258	262	ADHD	T048	C1263846
28118752	264	285	augmenting stimulants	T120	C0449986
28118752	275	285	stimulants	T121	C0304402
28118752	291	318	guanfacine extended-release	T122	C1707968
28118752	320	323	GXR	T122	C1707968
28118752	326	344	Inclusion criteria	T078	C0243161
28118752	351	356	years	T079	C0439234
28118752	361	365	ADHD	T048	C1263846
28118752	366	375	diagnosis	T033	C0011900
28118752	380	391	long-acting	T121	C0304402
28118752	399	421	short-acting stimulant	T121	C0304402
28118752	427	430	GXR	T122	C1707968
28118752	431	443	augmentation	T061	C1293122
28118752	445	481	Modified medication possession ratio	T081	C0456603
28118752	483	487	mMPR	T081	C0456603
28118752	489	493	days	T079	C0439228
28118752	494	504	medication	T058	C2081612
28118752	505	514	available	T169	C0470187
28118752	517	521	days	T079	C0439228
28118752	525	531	period	T079	C1948053
28118752	533	542	excluding	T169	C0332196
28118752	543	553	medication	T058	C2081612
28118752	554	562	holidays	T052	C0019843
28118752	578	582	mMPR	T081	C0456603
28118752	590	601	nonadherent	T033	C3845923
28118752	603	613	Regression	T170	C0034980
28118752	614	620	models	T170	C3161035
28118752	621	629	assessed	T058	C0184514
28118752	630	636	change	T169	C0392747
28118752	640	644	mMPR	T081	C0456603
28118752	645	654	adjusting	T169	C0456081
28118752	659	670	demographic	T102	C0683970
28118752	675	699	clinical characteristics	T201	C0683325
28118752	707	715	patients	T101	C0030705
28118752	716	727	nonadherent	T033	C3845923
28118752	731	741	stimulants	T121	C0304402
28118752	742	745	pre	T079	C0332152
28118752	748	760	augmentation	T061	C1293122
28118752	772	782	unadjusted	T169	C1439367
28118752	789	791	SD	T081	C0871420
28118752	793	796	pre	T079	C0332152
28118752	803	807	post	T079	C0687676
28118752	810	819	stimulant	T121	C0304402
28118752	820	825	mMPRs	T081	C0456603
28118752	860	868	Adjusted	T169	C0456081
28118752	874	880	change	T169	C0392747
28118752	884	888	mMPR	T081	C0456603
28118752	902	913	long-acting	T121	C0304402
28118752	930	953	short-acting stimulants	T121	C0304402
28118752	972	980	patients	T101	C0030705
28118752	981	992	nonadherent	T033	C3845923
28118752	996	1006	stimulants	T121	C0304402
28118752	1008	1011	GXR	T122	C1707968
28118752	1012	1024	augmentation	T061	C1293122
28118752	1029	1044	associated with	T080	C0332281
28118752	1045	1054	increased	T081	C0205217
28118752	1055	1064	stimulant	T121	C0304402
28118752	1065	1074	adherence	T169	C1510802